EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Role of Bailout Gene-Silencing Therapy in Plaque Lipid Reduction: Intravascular Imaging Study

Baiba Kokina, Karlis Trusinskis, Baiba Kokina, Maris Lapsovs, Mairita Karantajere, Evija Kanasniece, Laima Caunite, Sanda Jegere, Inga Narbute, Dace Sondore, Alona Grave, Indulis Kumsars und 1 weitere

Cardiology · 2025

DOI: 10.1159/000543463 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cardiology, 2025. Verfasst von Baiba Kokina und 12 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine and Life Sciences, University of Latvia, Riga, Latvia. Hauptthemen laut MEDLINE: Plaque, Atherosclerotic, Coronary Artery Disease, Gene Silencing, Hypercholesterolemia. Die Arbeit nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Insufficient statin/ezetimibe effectiveness for low-density lipoprotein cholesterol (LDL-C) reduction is not uncommon. A novel gene-silencing medication inclisiran has been introduced. Near-infrared spectroscopy (NIRS) allows to assess the dynamics of plaque lipid content in the context of optimal lipid-lowering pharmacotherapy. The aim of this study was to evaluate the impact of optimal hypolipidaemic pharmacotherapy, including add-on inclisiran, on the plasma lipid profile and plaque lipid content.

Methods

This study enrolled patients with stable coronary artery disease, admitted for elective percutaneous coronary intervention (PCI). NIRS of the segment of interest was performed during index PCI and 15 months later. Patients having LDL-C >1.8 mmol/L after 4–6 weeks of maximum tolerated statin/ezetimibe therapy received add-on inclisiran. Lipid profile changes within 15 months were also evaluated.

Results

Among 42 included patients, 24 drug-resistant hypercholesterolaemia participants were assigned to inclisiran therapy. After 15 months, a significant LDL-C decrease of 26.42% was established (p = 0.006), with 12 participants reaching the LDL-C goal of

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Plaque, AtheroscleroticCoronary Artery DiseaseGene SilencingHypercholesterolemiaHumansMaleFemaleMiddle AgedCholesterol, LDLAgedPercutaneous Coronary InterventionSpectroscopy, Near-InfraredEzetimibeHydroxymethylglutaryl-CoA Reductase InhibitorsAnticholesteremic Agents

Stichwörter der Autor:innen

Gene silencingInclisiranIntravascular imagingLow-density lipoprotein cholesterolNear-infrared spectroscopy

Substanzen

Cholesterol, LDLEzetimibeHydroxymethylglutaryl-CoA Reductase InhibitorsAnticholesteremic Agents

Autor:innen und Institutionen

  • Faculty of Medicine and Life Sciences, University of Latvia, Riga, Latvia.
  • Latvian Centre of Cardiology, Pauls Stradins Clinical University Hospital, Riga, Latvia.
  • Department of Residency, Riga Stradins University, Riga, Latvia.
  • Department of Internal Diseases, Riga Stradins University, Riga, Latvia.

Zitieren

APA

Kokina, B., Trusinskis, K., Kokina, B., Lapsovs, M., Karantajere, M., Kanasniece, E., Caunite, L., Jegere, S., Narbute, I., Sondore, D., Grave, A., Kumsars, I., & Erglis, A. (2025). Role of Bailout Gene-Silencing Therapy in Plaque Lipid Reduction: Intravascular Imaging Study. Cardiology. https://doi.org/10.1159/000543463

Vancouver

Kokina B, Trusinskis K, Kokina B, Lapsovs M, Karantajere M, Kanasniece E, et al. Role of Bailout Gene-Silencing Therapy in Plaque Lipid Reduction: Intravascular Imaging Study. Cardiology. 2025. doi:10.1159/000543463

BibTeX
@article{Kokina2025,
  author = {Kokina, Baiba and Trusinskis, Karlis and Kokina, Baiba and Lapsovs, Maris and Karantajere, Mairita and Kanasniece, Evija and Caunite, Laima and Jegere, Sanda and Narbute, Inga and Sondore, Dace and Grave, Alona and Kumsars, Indulis and Erglis, Andrejs},
  title = {Role of Bailout Gene-Silencing Therapy in Plaque Lipid Reduction: Intravascular Imaging Study},
  journal = {Cardiology},
  year = {2025},
  doi = {10.1159/000543463}
}
Kostenlos starten →